Sun Pharmaceutical Industries Ltd (SUN.BO)

SUN.BO on Bombay Stock Exchange

811.20INR
26 Dec 2014
Price Change (% chg)

Rs6.50 (+0.81%)
Prev Close
Rs804.70
Open
Rs807.00
Day's High
Rs812.65
Day's Low
Rs804.00
Volume
84,807
Avg. Vol
192,502
52-wk High
Rs932.00
52-wk Low
Rs552.50

SUN.BO

Chart for SUN.BO

About

Sun Pharmaceutical Industries Limited is an international specialty pharma company. The Company manufactures and markets pharmaceutical formulations as branded generics, as well as generics in India, the United states and several other markets across the world. The Company’s business is divided into four segments: US Generics,... (more)

Overall

Beta: 0.61
Market Cap (Mil.): Rs1,680,025.00
Shares Outstanding (Mil.): 2,071.16
Dividend: 1.50
Yield (%): 0.18

Financials

  SUN.BO Industry Sector
P/E (TTM): 27.91 38.36 38.84
EPS (TTM): 29.07 -- --
ROI: 32.12 18.99 18.26
ROE: 31.49 19.74 19.12
Search Stocks

Deals of the day- Mergers and acquisitions

(Adds Mizuho, Oriola-KD, Sharp, Vattenfall, TriMas Corp, Abris Capital)

08 Dec 2014

CORRECTED-Deals of the day- Mergers and acquisitions

(Removes erroneous reference to Canadian Solar in Sharp Corp item)

08 Dec 2014

UPDATE 1-India's Ranbaxy books first profit in 6 quarters on exclusive drug launch

* Shares rise 6 pct, outpacing market (Adds details on results, shares, context)

28 Oct 2014

Merck licenses experimental psoriasis drug to India's Sun Pharma

- Merck & Co Inc said it had licensed its experimental psoriasis drug to Indian generic maker Sun Pharmaceutical Industries Ltd for $80 million.

17 Sep 2014

India regulator says Sun's takeover of Ranbaxy may hurt competition

MUMBAI - India's antitrust regulator said on Thursday it had made an initial observation that Sun Pharmaceutical Industries Ltd's agreed $3.2 billion acquisition of Ranbaxy Laboratories Ltd could hurt competition, asking the companies to provide more details.

04 Sep 2014

India regulator says Sun's takeover of Ranbaxy may hurt competition

MUMBAI, Sept 4 - India's antitrust regulator said on Thursday it had made an initial observation that Sun Pharmaceutical Industries Ltd's agreed $3.2 billion acquisition of Ranbaxy Laboratories Ltd could hurt competition, asking the companies to provide more details.

04 Sep 2014

India's Ranbaxy Laboratories posts loss in June quarter

MUMBAI, July 29 - Indian drugmaker Ranbaxy Laboratories Ltd, which has agreed to be acquired by local rival Sun Pharmaceutical Industries Ltd, posted a net loss in the June quarter hit by a one-time provision.

29 Jul 2014

India's Sun Pharma acquires U.S.-based Pharmalucence

MUMBAI, July 16 - Sun Pharmaceutical Industries Ltd, India's third-largest generic drugmaker by sales, said on Wednesday it had acquired U.S.-based Pharmalucence Inc, which has sterile injectable capacity and research capabilities.

15 Jul 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: GlobalData
$125.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: Wright Reports
$75.00
Provider: Reuters Investment Profile
$20.00
Provider: SMC Global Securities Limited
$12.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks